Infosys launches Agentic AI Foundry under Topaz to accelerate enterprise AI transformation
By Aditya Bhagchandani Published on May 28, 2025, 16:19 IST
Infosys on Wednesday announced the launch of its Agentic AI Foundry, part of its Topaz™ platform, aimed at helping enterprises develop and deploy AI agents at scale. The solution is designed to support reliable, production-grade AI agents across business operations, IT, and customer ecosystems.
The Foundry brings together a library of reusable components and pre-built agents, both horizontal and industry-specific, to simplify AI adoption. It enables enterprises to customize and integrate these agents across in-house or third-party platforms, avoiding vendor lock-in and supporting a future-ready, ethical AI architecture.
'At Infosys, we believe the future of innovation lies in harnessing the power of AI responsibly and effectively. Infosys Agentic AI Foundry is a game-changer in enterprise transformation,' said Balakrishna D. R. (Bali), EVP and Global Services Head, AI and Industry Verticals at Infosys.
For instance, the company has deployed a multi-agent invoice automation solution in its finance team, improving productivity by over 50% and delivering significant cost savings.
'The line between human capabilities and AI-powered software is rapidly blurring. Infosys' approach to Agentic AI is a critical move to support enterprises under pressure to embed these capabilities into their experiences,' added Phil Fersht, CEO of HFS Research.
Infosys also cited deployments at client organizations, such as a deep research agent reducing support resolution times by 50% and AI-powered audit agents enhancing financial record integrity.
The initiative aligns with Infosys' broader AI-first approach, promising cost efficiency, innovation, and seamless adoption of evolving AI technologies.
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
44 minutes ago
- Yahoo
Kontron Launches Brand-new 2.5"-SBC-AML/ADN Single Board Computer To Help Developers Realize Ultra-compact Or Portable AI-native Systems
TAIPEI, June 4, 2025 /PRNewswire/ -- Kontron, a global leader in smart IoT solutions, launches a brand-new Pico-ITX single board computer, 2.5"-SBC-AML/ADN, providing developers a low-power, real-time and AI-native computing platform to realize ultra-compact or even portable computing systems and appliances for diverse edge applications, including industrial automation, healthcare, smart city, smart retail, office automation, safety and security. Commercial & Industrial Variants Available 2.5"-SBC-AML/ADN is driven by commercial-grade Intel® Atom® x7000E Series, Intel® Core™ i3 N-Series, Intel® N-Series processors and industrial-grade Intel® Atom® x7000RE Series processors. To better unleash the processor's features, it is offered with commercial-grade operating temperature range of 0°C ~ 60°C and industrial-grade range of -40°C ~ 85°C to address more applications. More Power in Small Footprint In contrast to its footprint of around a credit card, 2.5"-SBC-AML/ADN unleashes incredible graphics performance. Three 4K@60fps displays can be driven via eDP, DisplayPort and DisplayPort over USB-C interfaces. Up to 32 execution units in iGPU and Intel® Deep Learning Boost AI acceleration capabilities deliver faster AI inference performance. What's more, all are enabled at a low TDP of 6W ~ 15W. Low Latency & Real-time 2.5"-SBC-AML/ADN is outfitted with high-speed soldered LPDDR5 4800MHz SDRAM, two higher-bandwidth 2.5GbE LAN ports, and three 10Gbps USB 3.2 Gen 2 Type A & C connectors, achieving ultra-low latency within and between the system and peripherals. Partial variants support Time-Sensitive Networking, ensuring real-time network responsiveness. More Rugged & Securer Besides soldered memory, 2.5"-SBC-AML/ADN comes with soldered eMMC storage and has intrinsic resistance to shock and vibration. It operates over a wide input range from DC 9V to 20V to accommodate to unstable power supply, surge or various voltage requirements in different applications. A discrete TPM 2.0 chip is integrated, providing securer hardware-based encryption. Uncompromising Connectivity & Expandability Despite its small footprint, 2.5"-SBC-AML/ADN doesn't skimp on connectivity and expandability. It reserves wiring interface options, including two COM ports and eight digital I/O channels, for industrial sensing and controlling, and two M.2 slots for Wi-Fi, 4G/5G, SSD or other possible expansions. For details, visit About Kontron Kontron champions IoT and Industry 4.0 with secure state-of-the-art solutions including hardware, software and services to speed market entry, reduce cost of ownership, and offer longevity, ensuring its role as a trusted partner in the integration of smart technologies. For more information, visit dial +886-2-2799-2789 or email SalesAsia@ View original content to download multimedia: SOURCE Kontron Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock
NEW HAVEN, Conn., June 3, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced the pricing of its previously announced underwritten public offering of 17,400,000 shares of its common stock at a public offering price of $5.75 per share, for total proceeds of $100 million, before deducting underwriting discounts and commissions and expenses payable by Trevi. All of the shares in the offering are being sold by Trevi. In addition, Trevi has granted the underwriters a 30-day option to purchase up to 2,610,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about June 5, 2025, subject to satisfaction of customary closing conditions. Morgan Stanley, Leerink Partners, Stifel and Cantor are acting as joint book-running managers for the offering. The shares are being offered by Trevi pursuant to a shelf registration statement on Form S-3 (File No. 333-273030), which was filed with the Securities and Exchange Commission (SEC) on June 29, 2023, amended on August 11, 2023 and declared effective by the SEC on August 15, 2023. This offering is being made only by means of a prospectus supplement and the accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC's website located at The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC. When available, copies of the preliminary prospectus supplement, final prospectus supplement and the accompanying prospectus may also be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, or by email at prospectus@ Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@ Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@ or Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, New York 10022, or by email at prospectus@ This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Trevi Therapeutics, Inc. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC). Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties and actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements about the anticipated closing of the public offering and the expected gross proceeds of the offering, among other things, and other statements containing the words "believes," "anticipates," "plans," "expects," "may," and similar expressions. Risks that contribute to the uncertain nature of the forward-looking statements include: uncertainties related to market conditions and whether the conditions for the closing of the public offering will be satisfied, as well as other risks and uncertainties, as well as other risks and uncertainties set forth in the "Risk Factors" section of the preliminary prospectus supplement filed with the SEC on June 2, 2025, in Trevi's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 filed with the SEC, and in any subsequent filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Trevi undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made except as required by law. Investor Contact Jonathan CarlsonTrevi Therapeutics, Inc.(203) 654 3286carlsonj@ Media Contact Rosalia Scampoli914-815-1465 rscampoli@ View original content to download multimedia: SOURCE Trevi Therapeutics, Inc.
Yahoo
an hour ago
- Yahoo
Kontron Launches Brand-new 2.5"-SBC-AML/ADN Single Board Computer To Help Developers Realize Ultra-compact Or Portable AI-native Systems
TAIPEI, June 4, 2025 /PRNewswire/ -- Kontron, a global leader in smart IoT solutions, launches a brand-new Pico-ITX single board computer, 2.5"-SBC-AML/ADN, providing developers a low-power, real-time and AI-native computing platform to realize ultra-compact or even portable computing systems and appliances for diverse edge applications, including industrial automation, healthcare, smart city, smart retail, office automation, safety and security. Commercial & Industrial Variants Available 2.5"-SBC-AML/ADN is driven by commercial-grade Intel® Atom® x7000E Series, Intel® Core™ i3 N-Series, Intel® N-Series processors and industrial-grade Intel® Atom® x7000RE Series processors. To better unleash the processor's features, it is offered with commercial-grade operating temperature range of 0°C ~ 60°C and industrial-grade range of -40°C ~ 85°C to address more applications. More Power in Small Footprint In contrast to its footprint of around a credit card, 2.5"-SBC-AML/ADN unleashes incredible graphics performance. Three 4K@60fps displays can be driven via eDP, DisplayPort and DisplayPort over USB-C interfaces. Up to 32 execution units in iGPU and Intel® Deep Learning Boost AI acceleration capabilities deliver faster AI inference performance. What's more, all are enabled at a low TDP of 6W ~ 15W. Low Latency & Real-time 2.5"-SBC-AML/ADN is outfitted with high-speed soldered LPDDR5 4800MHz SDRAM, two higher-bandwidth 2.5GbE LAN ports, and three 10Gbps USB 3.2 Gen 2 Type A & C connectors, achieving ultra-low latency within and between the system and peripherals. Partial variants support Time-Sensitive Networking, ensuring real-time network responsiveness. More Rugged & Securer Besides soldered memory, 2.5"-SBC-AML/ADN comes with soldered eMMC storage and has intrinsic resistance to shock and vibration. It operates over a wide input range from DC 9V to 20V to accommodate to unstable power supply, surge or various voltage requirements in different applications. A discrete TPM 2.0 chip is integrated, providing securer hardware-based encryption. Uncompromising Connectivity & Expandability Despite its small footprint, 2.5"-SBC-AML/ADN doesn't skimp on connectivity and expandability. It reserves wiring interface options, including two COM ports and eight digital I/O channels, for industrial sensing and controlling, and two M.2 slots for Wi-Fi, 4G/5G, SSD or other possible expansions. For details, visit About Kontron Kontron champions IoT and Industry 4.0 with secure state-of-the-art solutions including hardware, software and services to speed market entry, reduce cost of ownership, and offer longevity, ensuring its role as a trusted partner in the integration of smart technologies. For more information, visit dial +886-2-2799-2789 or email SalesAsia@ View original content to download multimedia: SOURCE Kontron Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
